View Older Stories View More Recent Stories
-
Incyte (INCY) and Novartis (NVS) entered into settlement agreement
-
WHO to Back Use of Weight-loss Drugs for Adults Globally, Raises Cost Issue - Reuters
-
Regulus Therapeutics (RGLS) to be Acquired by Novartis (NVS) for $7 Per Share
-
Novartis (NVS) Reports Q1 EPS of $2.28; offers outlook
-
HSBC cuts biotech stocks: Eli Lilly lowered to Reduce
-
Novartis (NVS) May 110 straddle priced into quarter results
-
BNP Paribas Exane Starts Novartis (NOVN:SW) (NVS) at Outperform
-
Novartis (NVS) plans to expand its US-based manufacturing and R&D footprint with a total investment of $23B over the next 5 years
-
Pharma stocks slide after Trump signals tariffs on sector
-
Novartis (NOVN:SW) (NVS) PT Raised to CHF115 at Deutsche Bank
-
Novartis receives third FDA approval for oral Fabhalta
-
Novartis named corporate pharmaceutical partner of the NFL
-
Increasing unusual option volume: AMKR UMC IVV PTEN TER NVS INFY VSCO
-
Novartis Holder Emasan Ag Offering About 26.5m Shares: Terms - Bloomberg
-
UBS Downgrades Novartis (NOVN:SW) (NVS) to Neutral
-
Morgan Stanley Starts Novartis (NOVN:SW) (NVS) at Underweight
-
Deutsche Bank Upgrades Novartis (NOVN:SW) (NVS) to Buy
-
Novartis (NVS) Tops Q4 EPS by 16c; offers guidance
-
Novartis (NVS) call put ratio 1 call to 1.7 puts with a focus on February 95 puts into quarter results
-
Novartis (NVS) call put ratio 1 call to 15.6 puts with a focus on February 95 puts
-
TD Cowen on Pharma: '10 Events in 2025 That Could Change Practice, Alter Companies, Move Stocks'
-
BioAge Labs (BIOA) Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions
-
Truist: 'Potential Impact of Trump's Nominees on Biopharma'
-
HSBC Downgrades Novartis (NOVN:SW) (NVS) to Reduce
-
JPMorgan Reiterates Overweight Rating on PTC Therapeutics (PTCT)
-
PTC Therapeutics (PTCT) Enters into a Global License and Collaboration Agreement with Novartis (NVS) for PTC518 Huntington's Disease Program
-
BMO Capital Reiterates Outperform Rating on Novartis (NVS)
-
Novartis (NVS) PT Raised to $120 at BMO Capital
-
Novartis (NVS) Tops Q3 EPS by 12c
-
Novartis (NVS) call put ratio 5 calls to 1 put into quarter results
-
Monte Rosa Therapeutics (GLUE) Announces Global License Agreement with Novartis (NVS) to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
-
Novartis (NVS) call put ratio 1 call to 4.1 puts into quarter results
-
TD Cowen Reiterates Hold Rating on Novartis (NVS)
-
Novartis' (NVS) Kisqali Approved by FDA to Reduce Risk of Recurrence in People With HR+/HR2- Early Breast Cancer
-
BofA Securities Downgrades Novartis (NOVN:SW) (NVS) to Neutral
-
BMO Capital Reiterates Market Perform Rating on Novartis (NVS)
-
Erste Group Upgrades Novartis (NVS) to Buy, 'currently valued below the sector average despite the good growth prospects'
-
Voyager Therapeutics (VYGR) Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
-
Goldman Sachs Downgrades Novartis (NVS) to Neutral
-
Goldman Sachs Downgrades Novartis (NOVN:SW) (NVS) to Neutral
-
Jefferies Downgrades Novartis (NVS) to Hold
-
Jefferies Downgrades Novartis (NOVN:SW) (NVS) to Hold
-
These 5 stocks are new additions to Bernstein's CEO Value Index
-
Novartis (NVS) twice-yearly Leqvio demonstrated clinically meaningful, statistically significant LDL-C lowering as a monotherapy in patients at low or moderate ASCVD risk
-
Novartis (NVS) and Lindy Biosciences Enter Licensing and Collaboration Agreement
-
FDA Approved Novartis' (NVS) fabhalta for Reduction of Proteinuria in Adults with Primary Immunoglobulin A Nephropathy
-
Novartis (NOVN:SW) (NVS) PT Raised to CHF86 at Berenberg
-
Novartis (NVS) PT Raised to $118 at BMO Capital
-
Increasing unusual put option volume: NVS DPZ HUMA ELV CMG
-
Novartis (NVS) Tops Q2 EPS by 13c; offers outlook
